Another RCT by Singh et al. included a total of 10 RCTs with 29,325 patients (n = 16,900 GLP-1 RA, n = 12,425 placebo) and found that when compared to placebo, individuals treated with GLP-1 RAs noticed significantly lower rates of MI, revascularization, MACE, and all-cause death in overweight or obese patients without diabetes mellitus (7). Here, GLP1R is linked to diabetes mellitus.